All Articles

A frank discussion about managing cancer pain in the current opioid crisis environment.

Dr James provides a review of recent report from the American Cancer Society Cancer Action Network on barriers to patient enrollment in therapeutic clinical trials for cancer and the consensus recommendations for overcoming these challenges.

AONN+ to utilize legislative, regulatory, and policy advocacy to protect and promote the practice of oncology patient navigation in order to best serve individuals and families impacted by cancer.

The AONN+ Technology & Innovation (T&I) Committee focuses on using technology to support and facilitate patient navigation in 3 ways.

The target audience for this series includes physicians (medical and surgical oncologists, interventional radiologists), oncology nurse navigators, oncology nurses, pathologists, oncology pharmacists, and other stakeholders involved in delivering personalized care to cancer patients.

The Academy of Oncology Nurse & Patient Navigators (AONN+) is pleased to announce Dr Jill Biden as the Keynote Speaker for the Ninth Annual Navigation & Survivorship Conference.

The target audience for this series includes physicians (medical and surgical oncologists, interventional radiologists), oncology nurse navigators, oncology nurses, pathologists, oncology pharmacists, and other stakeholders involved in delivering personalized care to cancer patients.

On behalf of the Editorial Board of the Journal of Oncology Navigation & Survivorship (JONS), it's my pleasure to offer the current issue. Each month, we aim to present navigators with an array of topics relevant to their practice. To achieve our goal, we publish original navigation research, treatment updates, interviews, and navigation best practices. Some highlights from the current issue follow.

JONS talks with Ms Whitten and Dr Fox about Meredith’s Mission and the advances being made in the treatment of melanoma.

Nurse and patient navigators are uniquely qualified to advocate for minority participation in oncology clinical trials.